Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial.

Hunault-Berger M, Maillard N, Himberlin C, Recher C, Schmidt-Tanguy A, Choufi B, Bonmati C, Carré M, Couturier MA, Daguindau E, Marolleau JP, Orsini-Piocelle F, Delaunay J, Tavernier E, Lissandre S, Ojeda-Uribe M, Sanhes L, Sutton L, Banos A, Fornecker LM, Bernard M, Bouscary D, Saad A, Puyade M, Rouillé V, Luquet I, Béné MC, Hamel JF, Dreyfus F, Ifrah N, Pigneux A.

Blood Cancer J. 2017 Jun 2;7(6):e568. doi: 10.1038/bcj.2017.50. No abstract available.

PMID:
28574488
2.

Factors associated with an increased risk of vertebral fracture in monoclonal gammopathies of undetermined significance.

Piot JM, Royer M, Schmidt-Tanguy A, Hoppé E, Gardembas M, Bourrée T, Hunault M, François S, Boyer F, Ifrah N, Renier G, Chevailler A, Audran M, Chappard D, Libouban H, Mabilleau G, Legrand E, Bouvard B.

Blood Cancer J. 2015 Aug 28;5:e345. doi: 10.1038/bcj.2015.71.

3.

Results of a Prospective Study of High-Dose or Conventional Anthracycline-Cyclophosphamide Regimen Plus Radiotherapy for Localized Adult Non-Hodgkin's Primary Bone Lymphoma.

Schmidt-Tanguy A, Houot R, Lissandre S, Abgrall JF, Casassus P, Rodon P, Desablens B, Marolleau JP, Garidi R, Lamy T, Moles-Moreau MP, Damaj G.

Adv Hematol. 2014;2014:512508. doi: 10.1155/2014/512508. Epub 2014 Mar 2.

4.

The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia: New Insights Based on a Survey of 44 Cases.

Legrand F, Renneville A, Macintyre E, Mastrilli S, Ackermann F, Cayuela JM, Rousselot P, Schmidt-Tanguy A, Fain O, Michel M, de Jaureguiberry JP, Hatron PY, Cony-Makhoul P, Lefranc D, Sène D, Cottin V, Hamidou M, Lidove O, Baruchel A, Dubucquoi S, Bletry O, Preudhomme C, Capron M, Prin L, Kahn JE; on behalf of the French Eosinophil Network.

Medicine (Baltimore). 2013 Aug 26. [Epub ahead of print]

5.

Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients.

Schmidt-Tanguy A, Voswinkel J, Henrion D, Subra JF, Loufrani L, Rohmer V, Ifrah N, Belizna C.

J Thromb Haemost. 2013 Oct;11(10):1927-9. doi: 10.1111/jth.12363. No abstract available.

6.

Double umbilical cord blood transplantation for hematological malignancies: a long-term analysis from the SFGM-TC registry.

Wallet HL, Sobh M, Morisset S, Robin M, Fegueux N, Fürst S, Mohty M, Deconinck E, Fouillard L, Bordigoni P, Rio B, Sirvent A, Renaud M, Dhedin N, Tabrizi R, Maury S, Buzyn A, Michel G, Maillard N, Cahn JY, Bay JO, Yakoub-Agha I, Huynh A, Schmidt-Tanguy A, Lamy T, Lioure B, Raus N, Marry E, Garnier F, Balère ML, Gluckman E, Rocha V, Socié G, Blaise D, Milpied N, Michallet M.

Exp Hematol. 2013 Nov;41(11):924-33. doi: 10.1016/j.exphem.2013.05.297. Epub 2013 Jul 2.

PMID:
23831606
7.

High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study.

Gyan E, Damotte D, Courby S, Sénécal D, Quittet P, Schmidt-Tanguy A, Banos A, Le Gouill S, Lamy T, Fontan J, Maisonneuve H, Alexis M, Dreyfus F, Tournilhac O, Laribi K, Solal-Céligny P, Arakelyan N, Cartron G, Gressin R; GOELAMS Group.

Br J Haematol. 2013 Jul;162(2):240-9. doi: 10.1111/bjh.12379. Epub 2013 May 21.

PMID:
23692641
8.

Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.

Perrier L, Lefranc A, Pérol D, Quittet P, Schmidt-Tanguy A, Siani C, de Peretti C, Favier B, Biron P, Moreau P, Bay JO, Lissandre S, Jardin F, Espinouse D, Sebban C.

Appl Health Econ Health Policy. 2013 Apr;11(2):129-38. doi: 10.1007/s40258-013-0011-7.

PMID:
23435861
9.

Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies.

Damaj G, Duhamel A, Robin M, Beguin Y, Michallet M, Mohty M, Vigouroux S, Bories P, Garnier A, El Cheikh J, Bulabois CE, Huynh A, Bay JO, Legrand F, Deconinck E, Fegueux N, Clement L, Dauriac C, Maillard N, Cornillon J, Ades L, Guillerm G, Schmidt-Tanguy A, Marjanovic Z, Park S, Rubio MT, Marolleau JP, Garnier F, Fenaux I, Yakoub-Agha I.

J Clin Oncol. 2012 Dec 20;30(36):4533-40. doi: 10.1200/JCO.2012.44.3499. Epub 2012 Oct 29.

10.

Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.

Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E, Banos A, Jaccard A, Park S, Tournilhac O, Schiano-de Collela JM, Voillat L, Joly B, Le Gouill S, Saad A, Cony-Makhoul P, Vilque JP, Sanhes L, Schmidt-Tanguy A, Bubenheim M, Houot R, Diouf M, Marolleau JP, Béné MC, Martin A, Lamy T.

J Clin Oncol. 2013 Jan 1;31(1):104-10. doi: 10.1200/JCO.2012.43.7285. Epub 2012 Oct 29.

PMID:
23109692
11.

[Transfusion support of haematological malignancies in 2012: evolution of the recommendations].

Marchand T, Orvain C, Farhi J, Boyer F, Schmidt-Tanguy A.

Transfus Clin Biol. 2012 Nov;19(4-5):150-3. doi: 10.1016/j.tracli.2012.07.020. Epub 2012 Oct 4. French. No abstract available.

PMID:
23039957
12.

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.

Damm F, Kosmider O, Gelsi-Boyer V, Renneville A, Carbuccia N, Hidalgo-Curtis C, Della Valle V, Couronné L, Scourzic L, Chesnais V, Guerci-Bresler A, Slama B, Beyne-Rauzy O, Schmidt-Tanguy A, Stamatoullas-Bastard A, Dreyfus F, Prébet T, de Botton S, Vey N, Morgan MA, Cross NC, Preudhomme C, Birnbaum D, Bernard OA, Fontenay M; Groupe Francophone des Myélodysplasies.

Blood. 2012 Apr 5;119(14):3211-8. doi: 10.1182/blood-2011-12-400994. Epub 2012 Feb 17.

13.

Routine use of microarray-based gene expression profiling to identify patients with low cytogenetic risk acute myeloid leukemia: accurate results can be obtained even with suboptimal samples.

de la Blétière DR, Blanchet O, Cornillet-Lefèbvre P, Coutolleau A, Baranger L, Geneviève F, Luquet I, Hunault-Berger M, Beucher A, Schmidt-Tanguy A, Zandecki M, Delneste Y, Ifrah N, Guardiola P.

BMC Med Genomics. 2012 Jan 30;5:6. doi: 10.1186/1755-8794-5-6.

14.

[Refractory anaemia with ringed sideroblasts (RARS) associated with marked thrombocytosis: a provisional entity in the WHO classification of haematological malignancies].

Gérard J, Dubois-Galopin F, Gardembas-Pain M, Defaux JB, Schmidt-Tanguy A, Godon A, Geneviève F, Blanchet O, Ifrah N, Zandecki M.

Ann Biol Clin (Paris). 2005 Nov-Dec;63(6):653-9. Review. French.

15.

[Idiopathic hypereosinophilic syndrome: toward a new molecular-targeted therapy and a new cytomorphological and molecular definition].

Moles MP, Landry J, Roche-Lestienne C, Godon A, Schmidt-Tanguy A, Gardembas M, Le Clech C, Verret JL, Zandecki M, Blanchet O.

Ann Biol Clin (Paris). 2005 May-Jun;63(3):317-22. French.

Supplemental Content

Loading ...
Support Center